

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

NALOX-1 PHARMACEUTICALS, LLC,  
Petitioner,

v.

ADAPT PHARMA OPERATIONS LIMITED, and  
OPIANT PHARMACEUTICALS, INC.,  
Patent Owner.

---

IPR2019-00685, Patent 9,211,253 B2  
IPR2019-00688, Patent 9,468,747 B2  
IPR2019-00694, Patent 9,629,965 B2

---

Before: ERICA A. FRANKLIN, ZHENYU YANG, and MICHAEL A.  
VALEK, *Administrative Patent Judges*.

YANG, *Administrative Patent Judge*.

DECISION

Granting Patent Owner Adapt Pharma Operations Limited's  
Motion for *Pro Hac Vice* Admission of Ana C. Reyes  
37 C.F.R. § 42.10

IPR2019-00685, Patent 9,211,253 B2  
IPR2019-00688, Patent 9,468,747 B2  
IPR2019-00694, Patent 9,629,965 B2

On November 19, 2019, in each of the three above-captioned proceedings, Patent Owner filed an Amended Mandatory Notice, adding Adapt Pharma Operations Limited (“Adapt”) as Patent Owner. Paper 19. Adapt also filed a Power of Attorney, appointing Jessamyn S. Berniker (Reg. No. 72,328) as the lead counsel. Paper 20. Adapt further filed a Motion for *Pro Hac Vice* Admission of Ana C. Reyes (Paper 21), supported by the Declaration of Ms. Reyes (Ex. 2038). Adapt represents that Petitioner does not oppose this Motion. Paper 21, 7.

Upon review, we determine that Adapt’s Motion satisfies the requirements of 37 C.F.R. § 42.10(c), and there is good cause to admit Ms. Reyes *pro hac vice* in these proceedings.

It is

ORDERED that Adapt’s Motion for *Pro Hac Vice* Admission of Ana C. Reyes is *granted*;

FURTHER ORDERED that Ms. Reyes is authorized to represent Adapt only as back-up counsel in the above-referenced proceedings;

FURTHER ORDERED that Adapt is to continue to have a registered practitioner represent it as lead counsel in the above-referenced proceedings;

FURTHER ORDERED that Mr. Reyes shall comply with the Office Patent Trial Practice Guide, as updated by the Office Patent Trial Practice Guide August 2018 Update, 83 Fed. Reg. 39,989 (Aug. 13, 2018) and the July 2019 Update (84 Fed. Reg. 33,925 (July 16, 2019)), and the Board’s Rules of Practice for Trials, as set forth in Part 42 of 37 C.F.R; and

IPR2019-00685, Patent 9,211,253 B2  
IPR2019-00688, Patent 9,468,747 B2  
IPR2019-00694, Patent 9,629,965 B2

FURTHER ORDERED that Mr. Reyes shall be subject to the Office's disciplinary jurisdiction under 37 C.F.R. § 11.19(a), and the Office's Rules of Professional Conduct set forth in 37 C.F.R. §§ 11.101 *et seq.*

PETITIONER:

Yelee Kim  
Janine Carlan  
Richard Berman  
Bradford Frese  
Christopher Yaen  
[yelee.kim@arentfox.com](mailto:yelee.kim@arentfox.com)  
[janine.carlan@arentfox.com](mailto:janine.carlan@arentfox.com)  
[richard.berman@arentfox.com](mailto:richard.berman@arentfox.com)  
[bradford.frese@arentfox.com](mailto:bradford.frese@arentfox.com)  
[christopher.yaen@arentfox.com](mailto:christopher.yaen@arentfox.com)

PATENT OWNER OPIANT PHARMACEUTICALS, INC.:

Robert F. Green  
Jessica Tyrus Mackay  
[rgreen@greengriffith.com](mailto:rgreen@greengriffith.com)  
[jmackay@greengriffith.com](mailto:jmackay@greengriffith.com)